Canaccord lowered the firm’s price target on BioXcel Therapeutics to $18 from $20 and keeps a Buy rating on the shares. The firm saidf the company believes it has reached alignment with the FDA on the next steps for BXCL501 (sublingual dexmedetomidine film) for the acute treatment of agitation in Alzheimer’s disease (AD) as part of the TRANQUILITY program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- BioXcel aligns with FDA recommendation for Phase 3 trial for TRANQUILITY
- BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
- Bioxcel Therapeutics (BTAI) Q3 Earnings Cheat Sheet
- Largest borrow rate increases among liquid names
- BioXcel reports overall survival results from Phase 2 trial of BXCL701